KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income from Continuing Operations (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Income from Continuing Operations for 16 consecutive years, with 50000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 108.82% year-over-year to 50000.0, compared with a TTM value of 42000.0 through Sep 2025, up 101.05%, and an annual FY2024 reading of 2312000.0, up 69.97% over the prior year.
  • Income from Continuing Operations was 50000.0 for Q3 2025 at TherapeuticsMD, down from 545000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 48453000.0 in Q4 2022 and bottomed at 47420000.0 in Q3 2021.
  • Average Income from Continuing Operations over 5 years is 9566684.21, with a median of 1584000.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations surged 212.79% in 2022, then plummeted 103.27% in 2023.
  • Year by year, Income from Continuing Operations stood at 42960000.0 in 2021, then soared by 212.79% to 48453000.0 in 2022, then tumbled by 103.27% to 1584000.0 in 2023, then skyrocketed by 105.24% to 83000.0 in 2024, then crashed by 39.76% to 50000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for TXMD at 50000.0 in Q3 2025, 545000.0 in Q2 2025, and 636000.0 in Q1 2025.